Biotech Company** (Country) |
Product |
Pharma Partner (Country) |
Type Arrangement/Geographic Area/ Details (Date) |
Amrad Corp. (Australia; ASX:AML) |
Oprol (sameterol xinafoate) for asthma |
Glaxo Wellcome Australia Ltd. (unit of Glaxo Wellcome plc; NYSE:GLX) |
Amrad co-markets product in Australia (2/99) |
Aurora Biosciences Corp. |
Mutant green fluorescent proteins |
Clontech Laboratories Inc.* |
Clontech to apply technology to not-for-profit customers worldwide for non-commercial research with a "zip-lock" license; Clontech may also supply to for-profit customers for non-commercial research (direct license required from Aurora); Clontech pays up-front technology access fee and royalties on any tools sold (3/99) |
Centocor Inc. |
Retavase (recombinantreteplase) |
Covance (NYSE:CVD) |
Covance to manufacture product for U.S. and Canada; further terms ND (4/99) |
Fragmin (dalteperin sodium for injection) |
Pharmacia & Upjohn (NYSE:PNU) |
Centocor to promote product in U.S. after FDA approval; further details ND (3/99) |
|
Cypress Bioscience |
Prosorba column for rheumatoid arthritis |
Fresenius AG (Germany) |
Letter of intent for exclusive license and distribution agreement covering U.S., Europe, Latin America and, subject to certain conditions, Japan; Fresenius to have exclusive rights outside the U.S., where product will be jointly introduced (1/99) |
Entremed Inc. |
Angiostatin protein for anti-angiogenesis |
Covance Biotechnology Services (NYSE:CVD) |
Covance to provide large-scale GMP production of Angiostatin for further preclinical studies (3/99) |
Enzo Biochem Inc. (ASE:ENZ) |
Various products; reagents; DNA labeling technologies |
NEN Life Science Products Inc. |
NEN to distribute products globally; further details ND (1/99) |
FibroGen Inc.* |
Recombinant collagen |
Zeneca LifeScience Molecules (business unit of Zeneca Group; U.K.) |
Zeneca to provide process development and scale-up expertise for commercialization of multi-gene expression technology; further details ND (3/99) |
Gensia Sicor Inc. |
Oncology products portfolio |
Abbott Laboratories Inc. (NYSE:ABT) |
Abbott to market and distribute multi-source oncology products now under development; further terms ND (1/99) |
Genzyme Corp. |
Sepra products; adhesion barrier and coating solution |
Fresenius AG (Germany) |
Fresenius to distribute and market products in France, Germany, Australia, Switzerland and Luxembourg; further details ND (1/99) |
Geron Corp. |
Cell lines immortalized with telomerase enzyme |
Clontech Laboratories Inc |
Clontech to produce and sell products for the not-for-profit research market, and supply to biotechnology and pharmaceutical industries under licenses between Geron and the companies; Clontech gets up-front licensing fee; companies to share equally the operating profits from cell-line sales (3/99) |
Insite Vision Inc. |
AquaSite treatment for dry eye |
Global Damon Pharm (Korea) |
Global Damon to distribute AquaSite in Korea for 10 years, paying royalties to InSite; further terms ND (3/99) |
Integra LifeSciences Corp. |
Panafil for healing and debridement, and Accuzyme (enzymatic debridement agent used to remove necrotic tissue of wounds) |
Healthpoint Ltd.* |
Series of agreements to purchase Panafil product line, brand name and related equipment for $6.4M; Health-point also agreed to pay sales commissions to Integra for marketing Panafil and Accuzyme to podiatry market and for marketing Panafil to certain hospitals with burn centers; Healthpoint will be responsible for all product distribution and coordination and sales of both products in other markets (1/99) |
LifeCell Corp. |
Acellular tissue matrix for urology, gynecology procedures |
Boston Scientific Corp. (NYSE:BSX) |
Boston Scientific to distribute product worldwide; Life-Cell to pay distribution fee based on percentage of sales; funding to market development programs to be shared equally; joint oversight of clinical research and marketing programs (3/99) |
Ligand Pharmaceuticals Inc. |
Oncology products ONTAK, Panretin gel and capsules, Targretin gel and capsules |
Ferrer Internacional SA (Spain) |
Ferrer to market and distribute products in Spain, Portugal, Greece and Central and South America; Ferrer has exclusive rights for 10 years, subject to extension; Ligand gets $2.5M over next six months as registration services reimbursement, plus milestone payment on first registration of Targretin for breast cancer in any of its European markets; Ligand to exclusively supply Ferrer with all 5 products for marketing in the territories (3/99) |
The Liposome Co. |
Abelcet (lipid-based formulation of amphotericin B) |
Wyeth-Ayerst International (subsidiary of American Home Products; NYSE:AHP) |
Wyeth-Ayerst to market product in the U.K.; certain members of Liposome's U.K. sales force to join Wyeth-Ayerst's (3/99) |
LJL Biosystems Inc. |
Drug-discovery products |
Sumitomo Corp. (Japan) |
Sumitomo to exclusively sell products in Japan; further details ND(2/99) |
Martek Bisociences Corp. |
PBXL fluorescent dye products for assays |
Amersham Pharmacia Biotech Ltd. (Sweden) |
Pharmacia to supply products for market; further details ND (3/99) |
MGI Pharma Inc. |
Ridaura (auranofin), anti-rheumatic drug; Luxiq (betamethasone balerate) |
Connetics Corp. (NASDAQ:CNCT) |
MGI to promote products in U.S. in exchange for promotional fees; for Ridaura, MGI gets $250,000 per quarter for making certain number of sales calls, plus split of gross profits over first $7.5 million; for Luxiq, MGI gets split of profits from sales in rheumatology market; Connetics retains profits from dermatology sales (3/99) |
MitoKor Inc.* |
MitoLoad assay and softWare to diagnose Alzheimer's disease |
SRL Inc. (Japan) |
SRL acquires right to use product for diagnosing Alzheimer's disease and selecting candidates for clinical trials; SRL pays up-front payment and royalties on a per-test basis; further terms ND (2/99) |
Molecular Simulations Inc. (wholly owned subsidiary of Pharmacoepia Inc.) |
Software products |
Ryoka Systems Inc. (wholly owned subsidiary of Mitsubishi Chemical Ltd.; Japan) |
Ryoka exclusively distributes products to MSI customers in Japan, and commits to certain increased revenue levels for 24 months (3/99) |
Neoprobe Corp. |
Gamma-guided surgery products |
KOL Bio-Medical Instruments Inc.* |
KOL will market and promote Neoprobe's current and future products in the U.S.; further terms ND (3/99) |
Neuro-Biotech* (Canada) |
Diagnostic kits for stress-related and neuroscience-related conditions |
Tutimpex Trading Co. |
Tutimpex to commercialize products in the Middle East; further details ND (3/99) |
Procyte Corp. |
Iamin Hydrating Gel and other wound-care products |
Merck KgaA (Germany) |
Merck to market Iamin and other wound-care products in its Latin American regions (1/99) |
Graftcyte, Complex Cu3 for skin repair, Tricomin for thinning hair, and other physician label products |
Sigmacon Medical Products* (Canada) |
Sigmacon to market products in dermatology, cosmetic and surgery markets in Canada; further terms ND (3/99) |
|
QLT Phototherapeutics Inc. |
Visudyne (verteporfin) for ophthalmic conditions |
Raylo Chemicals Inc. (Canada); Nippon Fine Chemical Co. (Japan); Parkedale Pharmaceuticals Inc. (wholly owned subsidiary of King Pharmaceuticals Inc.) |
Raylo to manufacture active ingredient; Nippon to manufacture formulated intermediate; Parkedale to manufacture finished, lypholized product; further terms ND (3/99) |
Synapse Technologies Inc.* (Canada) |
p97 diagnostic assay for Alzheimer's disease |
Kyowa Medex Co. (Japan) |
Kyowa provides Synapse with up-front and pre-launch milestone payments exceeding C$2.5 million, in exchange for exclusive promotion rights in Japan (3/99) |
Unigene Laboratories Inc. |
Forcaltonin injectable calcium for Paget's disease |
Strakan Ltd. (U.K.) |
Strakan distributes product to hospitals and pharmacies in the U.K. and Ireland upon marketing authorization, paying royalties to Unigene (1/99) |
Zonagen Inc. |
Vasomax (phentolamine mesylate) for erectile dysfunction |
Schering-Plough Corp. (NYSE:SGP) |
Schering-Plough exercises right to begin manufacturing product, which is under review by the FDA; further terms ND (2/99) |
| |||
To read more on related topics, click on one of the words below.